CD90-(Thy-1-) high selection enhances reprogramming capacity of murine adipose-derived mesenchymal stem cells

Disease Markers

Volumn 35, Issue 5, 2013, Pages 573-579

  Kawamoto, Koichi ^a   Konno, Masamitsu ^a   Nagano, Hiroaki ^a   Nishikawa, Shimpei ^a   Tomimaru, Yoshito ^a   Akita, Hirofumi ^a   Hama, Naoki ^a   Wada, Hiroshi ^a   Kobayashi, Shogo ^a   Eguchi, Hidetoshi ^a   Tanemura, Masahiro ^b   Ito, Toshinori ^a   Doki, Yuichiro ^a   Mori, Masaki ^a   Ishii, Hideshi ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b NATIONAL HOSPITAL ORGANIZATION   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CELL MARKER; KRUPPEL LIKE FACTOR 4; MYC PROTEIN; OCTAMER TRANSCRIPTION FACTOR 4; THY 1 ANTIGEN; TRANSCRIPTION FACTOR SOX2;

ADIPOSE TISSUE; ADIPOSE TISSUE CELL; ADIPOSE TISSUE DERIVED MESENCHYMAL STEM CELL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL ISOLATION; CELL SELECTION; CELL SUBPOPULATION; CELL THERAPY; CELL TYPE; CONTROLLED STUDY; EMBRYO; FLUORESCENCE ACTIVATED CELL SORTING; GRAFT REJECTION; HUMAN; HUMAN CELL; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOREGULATION; MESENCHYMAL STEM CELL; MOUSE; NONHUMAN; NUCLEAR REPROGRAMMING; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; STANDARD; STEM CELL TRANSPLANTATION; THYMOCYTE;

MURINAE; MUS;

ADIPOSE TISSUE; ANIMALS; ANTIGENS, THY-1; BIOLOGICAL MARKERS; CELL DIFFERENTIATION; FLOW CYTOMETRY; HEK293 CELLS; HUMANS; MESENCHYMAL STROMAL CELLS; MICE; NUCLEAR REPROGRAMMING;

EID: 84890350256     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2013/392578     Document Type: Article

References (18)

1. K. Takahashi and S. Yamanaka, "Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors," Cell, vol. 126, no. 4, pp. 663-676, 2006.
2. S.Wakao,M.Kitada,Y.Kuroda et al., "Multilineage-differentiating stress-enduring(Muse) cells are a primary source of induced pluripotent stem cells in human fibroblasts," Proceedings of the National Academy of Sciences of the United States of America, vol. 108, no. 24, pp. 9875-9880, 2011.
3. S. Eminli, A. Foudi, M. Stadtfeld et al., "Differentiation stage determines potential of hematopoietic cells for reprogramming into induced pluripotent stem cells,"Nature Genetics, vol. 41,no. 9, pp. 968-976, 2009.
4. M. T. Chung, C. Liu, J. S. Hyun et al., "CD90 (Thy-1)-positive selection enhances osteogenic capacity of human adiposederived stromal cells," Tissue Engineering A, vol. 19, pp. 989-997, 2013.
5. K. Le Blanc and D. Mougiakakos, "Multipotent mesenchymal stromal cells and the innate immune system," Nature Reviews Immunology, vol. 12, no. 5, pp. 383-396, 2012.
6. M. Konno, A. Hamabe, S. Hasegawa et al., "Adipose-derived mesenchymal stem cells and regenerative medicine," Development, Growth and Differentiation, vol. 55, pp. 309-318, 2013.
7. Y. Ohmura, M. Tanemura, N. Kawaguchi et al., "Combined transplantation of pancreatic islets and adipose tissue-derived stem cells enhances the survival and insulin function of islet grafts in diabetic mice," Transplantation, vol. 90, no. 12, pp. 1366-1373, 2010.
8. T. Y. Yeung, K. L. Seeberger, T. Kin et al., "Human mesenchymal stem cells protect human islets from pro-inflammatory cytokines," PLoS ONE, vol. 7, Article IDe38189, 2012.
9. J. Tan, W. Wu, X. Xu et al., "Induction therapy with autologous mesenchymal stem cells in living-related kidney transplants: a randomized controlled trial," Journal of the American Medical Association, vol. 307, no. 11, pp. 1169-1177, 2012.
10. Y. Peng, M. Ke, L.Xu et al., "Donor-derivedmesenchymal stem cells combined with low-dose tacrolimus prevent acute rejection after renal transplantation: a clinical pilot study," Transplantation, vol. 95, pp. 161-168, 2013.
11. M. E. Reinders, J. W. de Fijter, H. Roelofs et al., "Autologous bone marrow-derived mesenchymal stromal cells for the treatment of allograft rejection after renal transplantation: results of a phase I study," Stem Cells Translational Medicine, vol. 2, pp. 107-111, 2013.
12. S. Nishikawa, M. Konno, A. Hamabe et al., "Aldehyde dehydrogenase high gastric cancer stem cells are resistant to chemotherapy," International Journal of Oncology, vol. 42, pp. 1437-1442, 2013.
13. K. H. Tang, Y. D. Dai, M. Tong et al., "A CD90(+) tumorinitiating cell population with an aggressive signature and metastatic capacity in esophageal cancer," Cancer Research, vol. 73, pp. 2322-2332, 2013.
14. C. K. Chan, P. Lindau,W. Jiang et al., "Clonal precursor of bone, cartilage, and hematopoietic niche stromal cells," Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 31, pp. 12643-12648, 2013.
15. M. A. González, E. Gonzalez-Rey, L. Rico, D. Büscher, and M. Delgado, "Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune responses," Gastroenterology, vol. 136, no. 3, pp. 978-989, 2009.
16. K. Okita, M. Nakagawa, H. Hyenjong, T. Ichisaka, and S. Yamanaka, "Generation of mouse induced pluripotent stem cells without viral vectors," Science, vol. 322, no. 5903, pp. 949-953, 2008.
17. N. Miyoshi, H. Ishii, H. Nagano et al., "Reprogramming of mouse and human cells to pluripotency using mature microRNAs," Cell Stem Cell, vol. 8, no. 6, pp. 633-638, 2011.
18. F. Anokye-Danso, C. M. Trivedi, D. Juhr et al., "Highly efficient miRNA-mediated reprogramming of mouse and human somatic cells to pluripotency," Cell Stem Cell, vol. 8, no. 4, pp. 376-388, 2011.